The Latest

  • A thumbnail illustration for BioPharma Blog's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Blog
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Alumis outlined plans for an offering that, if successful, would be the third by an immune drug developer this year.

    Updated June 9, 2024
  • People walk past the Nasdaq MarketSite on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Radiopharma drugmaker Telix pulls US IPO plans

    The Australia-based company had proposed raising $202 million via an initial stock sale, but withdrew its filing, citing its shares’ recent price appreciation on Australia’s stock exchange.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing

    The Japanese pharma paid $100 million to secure option rights to an Ascentage drug. Elsewhere, J.P. Morgan Private Capital closed its first fund and the FDA gave new COVID shot advice.

  • A headshot of Peter Emtage, CEO of Santa Ana Therapeutics.
    Image attribution tooltip
    Permission granted by Versant Ventures
    Image attribution tooltip
    Emerging biotech

    Versant debuts biotech working on ‘anger management for the immune system’

    Investor enthusiasm for precision immunology medicines is providing a tailwind for Santa Ana Therapeutics, a new startup backed by Versant, GV and a16z, among others.

  • a nurse gives a vaccination to a woman sitting in a chair
    Image attribution tooltip
    Joe Raedle/Getty Images via Getty Images
    Image attribution tooltip

    Moderna says next-gen COVID shot effective in study

    Trial data suggest the shot — an important component of an upcoming combination inoculation — has proven at least as effective, and in some cases superior, to the company’s initial COVID vaccine.

  • An illustration for BioPharma Blog's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Blog
    Image attribution tooltip
    Deep Dive

    Biotech M&A is on the upswing. Track the latest deals here.

    Eleven private biotech companies have been acquired through May, putting 2024 on pace to be a particularly strong year for startup M&A.

    Updated May 29, 2024
  • People pass an office building with signage spelling Pfizer in New York City.
    Image attribution tooltip
    George Clerk via Getty Images
    Image attribution tooltip

    Pfizer gene therapy for Duchenne fails to meet goals of key trial

    The negative results from the Phase 3 study, called Ciffreo, come a little more than a month after Pfizer said a patient died in another trial of the gene therapy.

  • A red magnifying glass sits on top of cash.
    Image attribution tooltip
    Pla2Na via Getty Images
    Image attribution tooltip

    Foresite, a biotech venture firm, reloads with $900M fund

    Amid some optimism for biotech startups, the firm sees opportunities to fund companies “at all stages of the productive development life cycle,” said managing director Vik Bajaj.

  • Close up of conference room with glasses of water on the table with papers, armchairs and a large window.
    Image attribution tooltip
    Igor Kutyaev via Getty Images
    Image attribution tooltip

    Regenxbio CEO to step down after 15 years

    Kenneth Mills will become chair of the gene therapy developer's board while Curran Simpson, the current chief operating officer, will take his place as company head.

  • Pfizer's logo cast in metal.
    Image attribution tooltip
    Jeenah Moon via Getty Images
    Image attribution tooltip
    Obesity drugs

    Flagship taps startup to hunt for obesity drugs that might interest Pfizer

    The venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates that Pfizer can choose to advance under a partnership it struck with Flagship last year.

  • A stylized illustration of a "patent thicket" for Jonathan Gardner's Nov. 1 story on Amgen's Enbrel.
    Image attribution tooltip
    Adeline Kon / BioPharma Blog/BioPharma Blog
    Image attribution tooltip
    Deep Dive // Patent thickets

    Drug patents protect pharma profits. Track when they’ll expire here.

    Intellectual property is the foundation of the drug industry’s business model. This database will track key patent expiry dates for 30 top-selling medicines.

    Updated May 13, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss

    Study results indicated Avidity’s medicine muted target genes. Elsewhere, Syntis revealed obesity drug plans and Nodthera chalked up more positive data for its NLRP3 inhibitor.

  • Image attribution tooltip

    Image courtesy of Ultragenyx.

    Image attribution tooltip

    Ultragenyx, Mereo drug reduces fractures in bone disorder study

    New data show the treatment’s effect on fractures and bone density held up over time, boosting the drug’s prospects ahead of a Phase 3 readout.

  • A U.S. flag flying above a building showing a sign with the word Lilly written in red.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    New Alzheimer's drugs

    Lilly Alzheimer’s drug gets unanimous backing of FDA panel

    The expert committee's twin 11-0 votes tees up donanemab for U.S. approval later this year and a market showdown with Leqembi.

    Updated June 11, 2024
  • An illustration of human liver anatomy against a stylized background.
    Image attribution tooltip
    Rasi Bhadramani via Getty Images
    Image attribution tooltip

    Ipsen drug for rare liver disease approved by FDA

    The medicine will join Intercept’s Ocaliva as a treatment option for primary biliary cholangitis. Another drug, from the now Gilead-owned CymaBay, could be cleared for the condition by August.

  • The Moderna headquarters is seen on November 30, 2020 in Cambridge, Massachusetts.
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip

    Moderna says combination flu, COVID shot succeeds in study

    Positive results from the trial could position Moderna to bring the two-in-one vaccine to market in 2025.

  • People walk past the Nasdaq MarketSite on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Alumis readies IPO to fund rival drug to Bristol Myers’ Sotyktu

    The offering will help fund Phase 3 tests of a drug the biotech claims could be more selective and potent than Bristol’s TYK2 inhibitor.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip

    Geron wins long-sought drug approval; Califf talks China, GLP-1s at BIO

    After 34 years, Geron finally has an approved medicine in Rytelo. Elsewhere, Shionogi disclosed disappointing obesity drug data and AbbVie got some good trial news.

  • An image of a periodic table entry for the chemical element lutetium
    Image attribution tooltip
    Lark Andrew Balcita via Getty Images
    Image attribution tooltip

    Germany’s ITM raises $205M as radiopharma field booms

    The funding will help ITM advance a pipeline that includes a potential competitor to Novartis' neuroendocrine cancer treatment Lutathera.

  • Image attribution tooltip
    Warren Little via Getty Images
    Image attribution tooltip

    GSK acquires oligonucleotide drug startup Elsie

    The deal, worth up to $50 million, adds to a pipeline GSK is building around nucleic acid drugs, including its hepatitis B candidate bepirovirsen.

  • A sign reading Food and Drug Administration is seen above a door to a government building.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA advisers back updating COVID shots to target JN.1 virus family

    The unanimous recommendation from the panel should help Novavax, which would have had difficulty adapting its shot in time if the committee picked a more specific subvariant.

    FDA
  • Seres Therapeutics' microbiome pill Vowst for recurrent C. diff. infections.
    Image attribution tooltip
    Courtesy of Seres Therapeutics
    Image attribution tooltip

    Seres, indebted and in need of cash, agrees to sell microbiome pill to Nestle

    Seres did not disclose financial details for the deal, but said it would help extend the company's cash runway by one year.

  • A 3D illustration showing amyloid plaques in brain tissue
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip
    New Alzheimer's drugs

    In review of Lilly Alzheimer’s drug, FDA staff focus on safety, patient selection

    An advisory panel is meeting today to discuss whether donanemab is effective across different groups of Alzheimer's patients, and to give input on an unusual dosing strategy used by Lilly.

  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly CFO leaves to join Alphabet

    Anat Ashkenazi is switching industries after a 23-year career at the Indianapolis drugmaker.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks

    A study abstract shed more light on tirzepatide’s potential in MASH. Elsewhere, Cytokinetics CEO spoke on deal negotiations and AbbVie started a key multiple myeloma drug study.